Limited Offer
Advances in Cancer Research
- 1st Edition, Volume 131 - July 19, 2016
- Editors: Kenneth D. Tew, Paul B. Fisher
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 0 4 7 8 8 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 5 1 8 0 - 1
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are prese… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
- Provides information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
- No. of pages: 208
- Language: English
- Edition: 1
- Volume: 131
- Published: July 19, 2016
- Imprint: Academic Press
- Hardback ISBN: 9780128047880
- eBook ISBN: 9780128051801
KT
Kenneth D. Tew
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
PF